Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 6 de 6
Filtrar
Más filtros










Base de datos
Intervalo de año de publicación
1.
Eur J Nucl Med Mol Imaging ; 37(7): 1377-85, 2010 Jul.
Artículo en Inglés | MEDLINE | ID: mdl-20140612

RESUMEN

PURPOSE: In vivo imaging of the spread of oncolytic viruses using the Na/I symporter (NIS) has been proposed. Here, we assessed whether the presence of NIS in the viral genome affects the therapeutic efficacy of the oncolytic adenovirus dl922-947 following intraperitoneal administration, in a mouse model of peritoneal ovarian carcinoma. METHODS: We generated AdAM7, a dl922-947 oncolytic adenovirus encoding the NIS coding sequence. Iodide uptake, NIS expression, infectivity and cell-killing activity of AdAM7, as well as that of relevant controls, were determined in vitro. In vivo, the propagation of this virus in the peritoneal cavity of tumour-bearing mice was determined using SPECT/CT imaging and its therapeutic efficacy was evaluated. RESULTS: In vitro infection of ovarian carcinoma IGROV-1 cells with ADAM7 led to functional expression of NIS. However, the insertion of NIS into the viral genome resulted in a loss of efficacy of the virus in terms of replication and cytotoxicity. In vivo, on SPECT/CT imaging AdAM7 was only detectable in the peritoneal cavity of animals bearing peritoneal ovarian tumours for up to 5 days after intraperitoneal administration. Therapeutic experiments in vivo demonstrated that AdAM7 is as potent as its NIS-negative counterpart. CONCLUSION: This study demonstrated that despite the detrimental effect observed in vitro, insertion of the reporter gene NIS in an oncolytic adenovirus did not affect its therapeutic efficacy in vivo. We conclude that NIS is a highly relevant reporter gene to monitor the fate of oncolytic adenovectors in live subjects.


Asunto(s)
Adenoviridae/fisiología , Genes Reporteros/genética , Imagen Molecular/métodos , Virus Oncolíticos/fisiología , Neoplasias Peritoneales/virología , Simportadores/genética , Replicación Viral , Adenoviridae/genética , Animales , Línea Celular Tumoral , Femenino , Regulación Neoplásica de la Expresión Génica , Genoma Viral/genética , Inyecciones Intraperitoneales , Ratones , Virus Oncolíticos/genética , Neoplasias Ováricas/genética , Neoplasias Ováricas/terapia , Neoplasias Ováricas/virología , Neoplasias Peritoneales/genética , Neoplasias Peritoneales/terapia
2.
Clin Cancer Res ; 15(21): 6595-601, 2009 Nov 01.
Artículo en Inglés | MEDLINE | ID: mdl-19861465

RESUMEN

PURPOSE: The Na/I symporter (hNIS) promotes concentration of iodine in cells. In cancer gene therapy, this transgene has potential as a reporter gene for molecular imaging of viral biodistribution and as a therapeutic protein promoting (131)I-mediated radiotherapy. Here, we combined the imaging and therapeutic potential of hNIS in an oncolytic adenoviruses targeting colorectal cancer cells. EXPERIMENTAL DESIGN: We generated an adenovirus (AdIP2) encoding hNIS and capable of selective replication in colorectal carcinoma cells. The selectivity of this virus was verified in vitro and in vivo. Its spread in tumors was monitored in vivo using single-photon emission computed tomography/CT imaging upon (99m)TcO(4)(-) injection and confirmed by immunohistochemistry. Metabolic radiotherapy was done through injection of therapeutic doses of (131)I(-). RESULTS: We showed in vitro and in vivo the selectivity of AdIP2 and that hNIS expression is restricted to the target cells. Imaging and immunohistochemical data showed that viral spread is limited and that the point of maximal hNIS expression is reached 48 hours after a single intratumoral injection. Administration of a single therapeutic dose of (131)I at this time point led to a dramatic reduction in tumor size not observed in hNIS-negative viruses. CONCLUSIONS: This report showed for the first time that the combination of the imaging and therapeutic potentials of hNIS can be applied to oncolytic adenoviruses in experimental models of cancer.


Asunto(s)
Adenoviridae/genética , Neoplasias Colorrectales/diagnóstico por imagen , Neoplasias Colorrectales/terapia , Genes Reporteros , Terapia Genética/métodos , Radioisótopos de Yodo/uso terapéutico , Simportadores/genética , Proteínas Wnt/metabolismo , Animales , Línea Celular Tumoral , Diagnóstico por Imagen , Marcación de Gen , Vectores Genéticos , Ratones , Ratones Desnudos , Cintigrafía , Simportadores/metabolismo , Transgenes
3.
Cancer Res ; 69(6): 2655-62, 2009 Mar 15.
Artículo en Inglés | MEDLINE | ID: mdl-19258509

RESUMEN

The lack of safe and efficient systemic gene delivery vectors has largely reduced the potential of gene therapy in the clinic. Previously, we have reported that polypropylenimine dendrimer PPIG3/DNA nanoparticles are capable of tumor transfection upon systemic administration in tumor-bearing mice. To be safely applicable in the clinic, it is crucial to investigate the colloidal stability of nanoparticles and to monitor the exact biodistribution of gene transfer in the whole body of the live subject. Our biophysical characterization shows that dendrimers, when complexed with DNA, are capable of forming spontaneously in solution a supramolecular assembly that possesses all the features required to diffuse in experimental tumors through the enhanced permeability and retention effect. We show that these nanoparticles are of sizes ranging from 33 to 286 nm depending on the DNA concentration, with a colloidal stable and well-organized fingerprint-like structure in which DNA molecules are condensed with an even periodicity of 2.8 nm. Whole-body nuclear imaging using small-animal nano-single-photon emission computed tomography/computer tomography scanner and the human Na/I symporter (NIS) as reporter gene shows unique and highly specific tumor targeting with no detection of gene transfer in any of the other tissues of tumor-bearing mice. Tumor-selective transgene expression was confirmed by quantitative reverse transcription-PCR at autopsy of scanned animals, whereas genomic PCR showed that the tumor sites are the predominant sites of nanoparticle accumulation. Considering that NIS imaging of transgene expression has been recently validated in humans, our data highlight the potential of these nanoparticles as a new formulation for cancer gene therapy.


Asunto(s)
ADN/química , Técnicas de Transferencia de Gen , Nanopartículas/química , Polipropilenos/química , Animales , Coloides/química , ADN/genética , Dendrímeros/química , Estabilidad de Medicamentos , Femenino , Análisis de Fourier , Células HeLa , Humanos , Luz , Macrófagos/efectos de los fármacos , Macrófagos/metabolismo , Ratones , Ratones Endogámicos BALB C , Ratones Endogámicos C3H , Ratones Desnudos , Microscopía Electrónica de Transmisión/métodos , Plásmidos/química , Plásmidos/genética , Dispersión de Radiación , Trasplante Heterólogo
4.
Cancer Res ; 68(23): 9771-8, 2008 Dec 01.
Artículo en Inglés | MEDLINE | ID: mdl-19047156

RESUMEN

Radiation has been shown to up-regulate gene expression from adenoviral vectors in previous studies. In the current study, we show that radiation-induced dsDNA breaks and subsequent signaling through the mitogen-activated protein kinase (MAPK) pathway are responsible, at least in part, for this enhancement of transgene expression both in vitro and in vivo. Inhibitors of ataxia-telangiectasia-mutated, poly(ADP-ribose) polymerase-mutated, and DNA-dependent protein kinase (DNA-PK)-mediated DNA repair were shown to maintain dsDNA breaks (gammaH2AX foci) by fluorescence-activated cell sorting and microscopy. Inhibition of DNA repair was associated with increased green fluorescent protein (GFP) expression from a replication-defective adenoviral vector (Ad-CMV-GFP). Radiation-induced up-regulation of gene expression was abrogated by inhibitors of MAPK (PD980059 and U0126) and phosphatidylinositol 3-kinase (LY294002) but not by p38 MAPK inhibition. A reporter plasmid assay in which GFP was under the transcriptional control of artificial Egr-1 or cytomegalovirus promoters showed that the DNA repair inhibitors increased GFP expression only in the context of the Egr-1 promoter. In vivo administration of a water-soluble DNA-PK inhibitor (KU0060648) was shown to maintain luciferase expression in HCT116 xenografts after intratumoral delivery of Ad-RSV-Luc. These data have important implications for therapeutic strategies involving multimodality use of radiation, targeted drugs, and adenoviral gene delivery and provide a framework for evaluating potential advantageous combinatorial effects.


Asunto(s)
Adenoviridae/genética , Daño del ADN/fisiología , Reparación del ADN/fisiología , Vectores Genéticos/genética , Neoplasias/genética , Adenoviridae/fisiología , Animales , Línea Celular Tumoral , ADN de Neoplasias/efectos de la radiación , Proteína 1 de la Respuesta de Crecimiento Precoz/genética , Femenino , Expresión Génica/efectos de la radiación , Proteínas Fluorescentes Verdes/biosíntesis , Proteínas Fluorescentes Verdes/genética , Células HCT116 , Humanos , Luciferasas/biosíntesis , Luciferasas/genética , Ratones , Ratones Desnudos , Transducción de Señal/efectos de la radiación , Regulación hacia Arriba/efectos de la radiación , Replicación Viral
5.
Clin Cancer Res ; 14(15): 4915-24, 2008 Aug 01.
Artículo en Inglés | MEDLINE | ID: mdl-18676766

RESUMEN

PURPOSE: To assess the effects of external beam radiotherapy (EBRT) on adenoviral-mediated transgene expression in vitro and in vivo and to define an optimal strategy for combining sodium iodide symporter (NIS)-mediated (131)I therapy with EBRT. EXPERIMENTAL DESIGN: Expression of reporter genes [NIS, green fluorescent protein (GFP), beta-galactosidase (lacZ), and luciferase (Luc)] from replication-deficient adenoviruses was assessed in tumor cell lines under basal conditions and following irradiation. The effects of viral multiplicity of infection (MOI) and EBRT dose on the magnitude and duration of gene expression were determined. In vivo studies were done with Ad-CMV-GFP and Ad-RSV-Luc. RESULTS: EBRT increased NIS, GFP, and beta-galactosidase expression in colorectal, head and neck, and lung cancer cells. Radiation dose and MOI were important determinants of response to EBRT, with greatest effects at higher EBRT doses and lower MOIs. Radiation exerted both transductional (through increased coxsackie-adenoviral receptor and integrin alpha(v)) and nontransductional effects, irrespective of promoter sequence (CMV, RSV, hTR, or hTERT). Analysis of the schedule of EBRT followed by viral infection revealed maximal transduction at 24 hours. Radiation maintained increasing radioiodide uptake from Ad-hTR-NIS over 6 days, in direct contrast to reducing levels in unirradiated cells. The effects of EBRT in increasing and maintaining adenovirus-mediated transgene expression were also seen in vivo using GFP- and luciferase-expressing adenoviral vectors. CONCLUSIONS: Radiation increased the magnitude and duration of NIS gene expression from replication-deficient adenoviruses. The transductional effect is maximal at 24 hours, but radioiodide uptake is maintained at an elevated level over 6 days after infection.


Asunto(s)
Adenoviridae/genética , Regulación de la Expresión Génica , Terapia Genética/métodos , Neoplasias/terapia , Simportadores/genética , Animales , Línea Celular Tumoral , Terapia Combinada/métodos , Femenino , Vectores Genéticos , Humanos , Ratones , Ratones Desnudos , Trasplante de Neoplasias , Radioterapia/métodos
6.
Cancer Res ; 67(3): 1299-307, 2007 Feb 01.
Artículo en Inglés | MEDLINE | ID: mdl-17283167

RESUMEN

The telomerase RNA (hTR) and reverse transcriptase (hTERT) promoters are active in most cancer cells, but not in normal cells, and are useful for transcriptional targeting in gene therapy models. Telomerase-specific conditionally replicating adenoviruses (CRAd) are attractive vectors because they should selectively lyse tumor cells. Here, we compare CRAds, in which either the hTR or hTERT promoter controls expression of the adenovirus E1A gene. In replication-defective reporter adenoviruses, the hTR promoter was up to 57-fold stronger in cancer cells than normal cells and up to 49-fold stronger than hTERT. In normal cells, hTERT promoter activity was essentially absent. Doses of telomerase-specific CRAds between 1.8 and 28 infectious units per cell efficiently killed cancer cells, but normal cells required higher doses. However, CRAd DNA replication and E1A expression were detected in both cancer and normal cells. Overall, tumor specificity of the CRAds was limited compared with nonreplicating vectors. Surprisingly, both CRAds expressed similar E1A levels and functional behavior, despite known differentials between hTR and hTERT promoter activities, suggesting that the promoters are deregulated. Rapid amplification of cDNA ends analysis of hTR-/hTERT-E1A transcripts ruled out cryptic transcription from the vector backbone. Blocking E1A translation partially restored the hTR-/hTERT-E1A mRNA differential, evidencing feedback regulation by E1A.


Asunto(s)
Adenoviridae/genética , Virus Oncolíticos/genética , ARN/genética , Telomerasa/genética , Adenoviridae/enzimología , Adenoviridae/patogenicidad , Adenoviridae/fisiología , Proteínas E1A de Adenovirus/biosíntesis , Proteínas E1A de Adenovirus/genética , Secuencia de Bases , Línea Celular Tumoral , Humanos , Datos de Secuencia Molecular , Virus Oncolíticos/enzimología , Virus Oncolíticos/patogenicidad , Virus Oncolíticos/fisiología , Regiones Promotoras Genéticas , Replicación Viral
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA
...